Last $28.33 USD
Change Today -0.28 / -0.98%
Volume 120.8K
SGNT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 09/12/14 All times are local (Market data is delayed by at least 15 minutes).

sagent pharmaceuticals inc (SGNT) Snapshot

Open
$28.63
Previous Close
$28.61
Day High
$28.65
Day Low
$27.99
52 Week High
09/4/14 - $29.39
52 Week Low
02/5/14 - $17.49
Market Cap
903.6M
Average Volume 10 Days
123.2K
EPS TTM
$0.43
Shares Outstanding
31.9M
EX-Date
--
P/E TM
66.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for SAGENT PHARMACEUTICALS INC (SGNT)

Related News

No related news articles were found.

sagent pharmaceuticals inc (SGNT) Related Businessweek News

No Related Businessweek News Found

sagent pharmaceuticals inc (SGNT) Details

Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, sources, manufactures, and markets pharmaceutical products, principally injectable-based generic equivalents to branded products in the United States. The company offers anti-infective products, such as Cefepime, an antibiotic used to treat infections of the urinary tract, and skin and skin structures, as well as moderate to severe pneumonia, intra-abdominal infections, and as empiric therapy for febrile neutropenic patients; and Levofloxacin, a fluoroquinolone antibacterial for the treatment of infections caused by susceptible bacteria, including nosocomial and community acquired pneumonia, sinusitis, chronic bronchitis, skin and skin structure infections, prostatitis, urinary tract infection, and pyelonephritis in adults of age 18 years or older. It also provides oncology products consisting of Docetaxel, an antineoplastic agent used to treat advanced or metastatic breast cancer after chemotherapy failure; Leucovorin Calcium, a folic acid derivative used to prevent harmful effects of methotrexate when methotrexate is used to treat certain types of cancer; and Zoledronic Acid, a bisphosphonate given intravenously to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer, as well as for treating osteoporosis. In addition, the company offers critical care products comprising Heparin, an anticoagulant used to prevent and treat blood clotting during and after surgery and dialysis. As of December 31, 2013, its product portfolio included 53 marketed products. It sells its products to hospitals, integrated delivery networks, and alternative site facilities through pharmaceutical wholesalers and specialty distributors. The company was formerly known as Sagent Holding Co. and changed its name to Sagent Pharmaceuticals, Inc. in April 2011. Sagent Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Schaumburg, Illinois.

269 Employees
Last Reported Date: 03/7/14
Founded in 2006

sagent pharmaceuticals inc (SGNT) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $615.2K
President
Total Annual Compensation: $308.7K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $330.8K
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $312.7K
Executive Vice President of National Accounts...
Total Annual Compensation: $287.4K
Compensation as of Fiscal Year 2013.

sagent pharmaceuticals inc (SGNT) Key Developments

Sagent Pharmaceuticals Announces the Launch of Ibandronate Sodium Injection

Sagent Pharmaceuticals, Inc. announced the launch of Ibandronate Sodium Injection, a bisphosphonate, in a preservative-free, prefilled plastic syringe kit. According to IMS, for the 12 months ending July 2014, the US market for Ibandronate approximated $18 million. As with all products in Sagent's portfolio, Ibandronate features Sagent's PreventIV Measures(SM) packaging and labeling, designed to help reduce medication errors.

Sagent Pharmaceuticals Announces the Reintroduction of Irinotecan Hydrochloride Injection, USP

Sagent Pharmaceuticals, Inc. announced the reintroduction of Irinotecan Hydrochloride Injection, USP, an antineoplastic agent, in two preservative-free amber glass vials. According to IMS, for the 12 months ending June 2014, the US market for Irinotecan approximated $23 million. As with all products in Sagent's portfolio, Irinotecan features Sagent's PreventIV Measures(SM) packaging and labeling, designed to help reduce medication errors. Irinotecan Hydrochloride Injection, USP is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.

Sagent Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Month Ended June 30, 2014; Revised Earnings Guidance for the Year 2014

Sagent Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six month ended June 30, 2014. For the quarter, the company reported net revenue of $69,194,000 against $59,591,000 a year ago. The increase in revenue was primarily driven by $17.2 million in revenue from the launch of 26 new codes or presentations of ten new products since June 30, 2013, partially offset by decreased demand and price declines in zoledronic acid vials, which were launched at market formation in March 2013. Income from operations was $3,318,000 against $13,434,000 a year ago. Income before income taxes was $3,242,000 against $13,370,000 a year ago. Net income was $3,069,000 or $0.09 per diluted share against $13,370,000 or $0.46 per diluted share a year ago. Adjusted EBITDA was $13,219,000 against $912,000 a year ago. EBITDA was $6,096,000 against $14,234,000 a year ago. For the six months, the company reported net revenue of $140,063,000 against $119,802,000 a year ago. Income from operations was $9,950,000 against $23,321,000 a year ago. Income before income taxes was $9,575,000 against $23,208,000 a year ago. Net income was $23,208,000 or $0.81 per diluted share against $8,188,000 or $0.25 per diluted share a year ago. Adjusted EBITDA was $16,708,000 against $27,420,000 a year ago. EBITDA was $14,254,000 against $25,374,000 a year ago. For the fiscal 2014, the company expects net revenue to be in the range of $270 million to $290 million driven by 10 to 15 product launches. As a result of strong performance in the first half of the year, the company narrowed net revenue and earnings guidance to the upper end of the initial range. Adjusted gross profit as a percentage of net revenue is expected in the range of 26% to 30%, an increase from initial estimate of 24% to 28%. The company anticipates reported net income for fiscal 2014 to be in the range of breakeven to $10 million in earnings.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGNT:US $28.33 USD -0.28

SGNT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Lannett Co Inc $39.57 USD -0.50
Momenta Pharmaceuticals Inc $11.58 USD -0.01
OraSure Technologies Inc $7.56 USD -0.29
Pfizer Ltd/India 1,654 INR +106.25
SciClone Pharmaceuticals Inc $7.18 USD -0.21
View Industry Companies
 

Industry Analysis

SGNT

Industry Average

Valuation SGNT Industry Range
Price/Earnings 62.0x
Price/Sales 3.4x
Price/Book 3.7x
Price/Cash Flow 62.0x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAGENT PHARMACEUTICALS INC, please visit www.sagentpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.